VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that Dr. Rick Strassman, author of the book DMT: The Spirit Molecule and Algernon consultant, will be joining CEO Christopher J.


Previous articleAcid for Anxiety: Fast and Lasting Anxiolytic Effects of LSD
Next articleRevive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA